On August 1, 2025, United Therapeutics announced it entered into two accelerated share repurchase agreements to buy back $1 billion of its common stock, which includes significant initial shares being delivered on August 4, 2025. This initiative aims to enhance shareholder value and reflects the company's capital management strategy.